Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 8;33(1):30-41.e6.
doi: 10.1016/j.chom.2024.12.002. Epub 2024 Dec 27.

Commensal-pathogen dynamics structure disease outcomes during Clostridioides difficile colonization

Affiliations

Commensal-pathogen dynamics structure disease outcomes during Clostridioides difficile colonization

Skye R S Fishbein et al. Cell Host Microbe. .

Abstract

Gastrointestinal colonization by Clostridioides difficile is common in healthcare settings and ranges in presentation from asymptomatic carriage to lethal C. difficile infection (CDI). We used a systems biology approach to investigate why patients colonized with C. difficile have a range of clinical outcomes. Microbiota humanization of germ-free mice with fecal samples from toxigenic C. difficile carriers revealed a spectrum of virulence among clinically prevalent clade 1 lineages and identified candidate taxa, including Blautia, as markers of stable colonization. Using gnotobiotic mice engrafted with defined human microbiota, we validated strain-specific CDI severity across clade 1 strains isolated from patients. Mice engrafted with a community broadly representative of colonized patients were protected from severe disease across all strains without suppression of C. difficile colonization. These results underline the capacity of gut community structure to attenuate a diversity of pathogenic strains without inhibiting colonization, providing insight into determinants of stable C. difficile carriage.

Keywords: Clostridioides difficile; gastrointestinal infection; gut microbiome.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests E.R.D. has served as a consultant for Seres Therapeutics, Ferring Pharmaceuticals, AstraZeneca, Summit, Merck, Recursion, and Abbott and has received research support from Theriva Biologics, Ferring Pharmaceuticals, and Pfizer, all unrelated to this study.

Update of

Similar articles

References

    1. Balsells E, Shi T, Leese C, Lyell I, Burrows J, Wiuff C, Campbell H, Kyaw MH, and Nair H (2019). Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health 9, 010407. 10.7189/jogh.09.010407. - DOI - PMC - PubMed
    1. Miles-Jay A, Snitkin ES, Lin MY, Shimasaki T, Schoeny M, Fukuda C, Dangana T, Moore N, Sansom SE, Yelin RD, et al. (2023). Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit. Nat Med. 10.1038/s41591-023-02549-4. - DOI - PMC - PubMed
    1. Newcomer EP, Fishbein SRS, Zhang K, Hink T, Reske KA, Cass C, Iqbal ZH, Struttmann EL, Burnham CA, Dubberke ER, and Dantas G (2024). Genomic surveillance of Clostridioides difficile transmission and virulence in a healthcare setting. mBio, e0330023. 10.1128/mbio.03300-23. - DOI - PMC - PubMed
    1. Knight DR, Imwattana K, Kullin B, Guerrero-Araya E, Paredes-Sabja D, Didelot X, Dingle KE, Eyre DW, Rodriguez C, and Riley TV (2021). Major genetic discontinuity and novel toxigenic species in Clostridioides difficile taxonomy. Elife 10. 10.7554/eLife.64325. - DOI - PMC - PubMed
    1. Worley J, Delaney ML, Cummins CK, DuBois A, Klompas M, and Bry L (2021). Genomic Determination of Relative Risks for Clostridioides difficile Infection From Asymptomatic Carriage in Intensive Care Unit Patients. Clin Infect Dis 73, e1727–e1736. 10.1093/cid/ciaa894. - DOI - PMC - PubMed

LinkOut - more resources